571 results about "Retinal" patented technology

Methods and systems are provided for measuring a retinal sublayer characteristic of an eye. A plurality of axial scans are performed over an area of the retina of the eye. Reflections are measured during the axial scans to determine a plurality of sets of reflection intensity values. A given set of reflection intensity values is associated with one of the plurality of axial scans. A progressive refinement boundary detection algorithm is performed using the plurality of sets of reflection intensity values to determine at least one boundary location associated with the retinal sublayer for each of the plurality of sets of reflection intensity values. The retinal sublayer characteristic is determined in response to the determined boundary locations.

A method for enhancing vision of an eye includes a laser delivery system having a laser beam for ablating corneal material from the cornea of the eye. Measurements are made to determine an optical path difference between a plane wave and a wavefront emanating from the retina of the eye for a location at a surface of the cornea. An optical correction is provided to the laser delivery system for the location based on the optical path difference and refractive indices of media through which the wavefront passes. The optical correction includes dividing the optical path difference by a difference between an index of refraction of corneal material and an index of refraction of air. The laser beam is directed to the location on the surface of the cornea and corneal material ablated at the location in response to the optical correction to cause the wavefront to approximate the shape of the plane wave at that location.

One aspect of the invention provides a blood glucose monitoring system including a light source adapted to transmit light onto at least a portion of a retina of an eye of a subject; a sensor adapted to receive light from the retina; a data capture and analysis system adapted to calculate blood glucose concentration of the subject from the light received by the sensor; and support structure adapted to maintain positions of the light source and the sensor; wherein at least one of the light source and the sensor is further adapted to be implanted within the eye. Another aspect of the invention provides a method of determining blood glucose concentration of a subject including the steps of: transmitting light to a retina of an eye of the subject; receiving reflected light from the retina; and calculating blood glucose concentration from the reflected light, wherein one or both of the light source and sensor are disposed within the eye. The invention also provides a method of implanting a blood glucose monitor as well as a blood glucose monitor adapted to receive information from a sensor disposed within a subject's eye.

The invention provides surgical devices that provide access to the sub-retinal space using delicate traction to hold the sensory retina to create and maintain a patent sub-retinal space of sufficient size to introduce and perform treatments on the eye. Such treatments may include the introduction of illumination or imaging agents or tools, surgical tools, the infusion of pharmaceutical or biological agents, and the placement of grafts, transplants or implants and the closure of the site through the delivery of a sealant.

Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and / or to lower intraocular pressure.

A subject (12) observes an image on a display (10). A control (18) produces a fixation image at a selected position in the display, followed by a stimulus spaced from the fixation image. An eye position sensor (14) detects a saccade movement towards the stimulus. The stimulus is then replaced with a fixation image and the cycle repeated. The time taken to saccade plus the intensity of the stimulus are used to produce a retinal map of field of vision, or to assess other characteristics of the subject.

This invention provides use of a SARM compound or a composition comprising the same in treating a variety of diseases or conditions in a subject, including, inter-alia, a diabetes disease, and / or disorder such as cardiovascular disease, atherosclerosis, cerebrovascular conditions, diabetic nephropathy, diabetic neuropathy and diabetic retinopathy.

A system and method for obtaining information about the spatial distribution of photoreceptor activity and neural activity in the retina using simultaneously recorded multiple biopotential signals. The information thus gathered is used to assess retinal dysfunction due to trauma or disease. The biopotential signals are recorded from the surface of the eye and head using a plurality of electrodes, including those integral to a contact lens. The biopotential signals are recorded before, during and after the presentation of an optical stimulus to the subject eye. The recorded biopotential signals are then analyzed and interpreted to reveal the distribution of photoreceptor activity and neural activity across the retina. The analysis and interpretation of the biopotential signals is quantitative, and makes use of an electromagnetic model of the subject eye. The subject may be animal or human.

Disclosed are methods and systems for non-invasive neuromodulation of the Sphenopalatine Ganglion and associated neural structures vidian nerve and / or sphenopalatine nerve using an ultrasound transducer to treat migraine and cluster headaches as well as other indications such as neurologic and psychiatric conditions. Treatment may be unilateral or bilateral.

A defined serumfree medical solution for applications in Ophthalmology, that contains one or more cell nutrient supplements, and a growth factor(s) which maintains and enhances the preservation of eye tissues, including human corneal, retinal and corneal epithelial tissues at low to physiological temperatures (2 DEG C. to 38 DEG C.). This solution is composed of a defined aqueous nutrient and electrolyte solution, supplemented with a glycosaminoglycan(s), a deturgescent agent(s), an energy source(s), a buffer system(s), an antioxidant(s), membrane stabilizing agents, an antibiotic(s) and / or antimycotic agent(s), ATP or energy precursors, nutrient cell supplements, coenzymes and enzyme supplements, nucleotide precursors, hormonal supplements, non-essential amino acids, trace minerals, trace elements and a growth factor(s).

The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and / or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and / or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.

Disclosed are infant formulas and corresponding methods of using them to promote retinal health and vision development in infants. The formulas, which are free of egg phospholipids and comprise fat, protein, carbohydrate, vitamins, and minerals, including docosahexaenoic acid and, on a ready-to-feed basis, at least about 50 mcg / liter of lutein, wherein the weight ratio of lutein (mcg) to docosahexaenoic acid (mg) is from about 1:2 to about 10:1. The formulas are also believed to be especially useful in reducing the risk of retinopathy of prematurity in preterm infants.

A compound of the formula wherein R1 is: R5 is: and n, m, Z, R8, R9, R10 and R11 are as defined herein, useful in the treatment of diabetes, insulin resistance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, cataracts, hyperglycemia, hypercholesterolemia, hypertension, hyperinsulinemia, hyperlipidemia, atherosclerosis, and tissue ischemia, particularly, myocardial ischemia.

A method and system for detecting abnormalities in the properties of the walls of a subject's blood vessels by observing the characteristics of blood flow in vessels which are optically accessible, such as the retinal vasculature. A time sequenced series of images is taken, and the images are processed to eliminate the background and render erythrocyte motion visible. Information about the state of the inner wall of the blood vessel which has been imaged is obtained from the characteristics of this blood flow. This information can be extrapolated to provide information about the state of the blood vessels elsewhere in the subject. In addition, a system and method is described for detecting arteriosclerotic plaque on the walls of blood vessels by labeling the plaque with a molecular label having desired optical or radioactive properties, and directly imaging the plaque either in an optically accessible blood vessel, or by imaging radioactive label in the plaque in a blood vessel anywhere in the body.

General anaglyphs may be rendered using multiple primary colors to display the first and second images of stereoscopic images. Retinal rivalry in the anaglyphs may be avoided by using transformations which balance the brightness contrast in the first and second images. Certain primary colors may be advantageous for rendering anaglyphs in six, five, four, and three primary colors. A white primary color is advantageous for displaying a monochrome second image with a color first image. General anaglyphs may be dynamically created by a display apparatus using certain transformations and communication with external sources. Four-primary-color anaglyphs may be compressed into three channels for transfer to a display apparatus. A user may select the primary colors of the first and second images and the relative brightness of the second image. Several methods to display general anaglyphs are disclosed.

A medical device for use on the human eye is described. The device is placed in an extrocular location in a patient and delivers an electrical current that stimulates the retina of patients who are blind or have vision disorders. It has at least one electrode that makes contact with the scleral surface of the eye, the electrode typically being activated by an electrical stimulator. The device produces electrical pulses which pass through the electrodes on the scleral surface of the eye, to activate the retina of the eye, which causes the patient to experience improved vision, visual sensations or the prevention of deterioration of vision. By this means, sight can be restored or improved where patients have disorders of their retina or other parts of their visual system.

Apparatus and methods are provided for reducing or eliminating the progression of myopia, including a lens having an intentionally created aberration pattern for reducing or eliminating the progression of myopia. The aberration pattern may comprise a positive spherical aberration that produces a wavefront error in which the paracentral wavefront is disposed in front of the retina, thereby producing a signal that counters axial length growth of the eye and preventing the progression of myopia.

The present invention relates to antagonists of vertebrate growth hormones obtained by mutation of the third alpha helix of such proteins (especially bovine or human GHs). These mutants-have growth-inhibitory or other GH-antagonizing effects. These novel hormones may be administered exogenously to animals, or transgenic animals may be made that express the antagonist. Animals have been made which exhibited a reduced growth phenotype. The invention also describes methods of treating acromegaly, gigantism, cancer, diabetes, vascular eye diseases (diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, retinopathy of sickle-cell anemia, etc.) as well as nephropathy and other diseases, by administering an effective amount of a growth hormone antagonist. The invention also provides pharmaceutical formulations comprising one or more growth hormone antagonists.

The present invention relates to a method of making novel dipeptidyl peptidase-IV ("DPP-IV') inhibitor compounds useful for treating, inter alia, diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes mellitus, metabolic syndrome (Syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of making 3,3,4,4-tetrafluoropyrrolidine, a starting material utilized in the afore-mentioned method for preparing DPP-IV compounds.

The present invention provides novel benzene compounds presented by the following formulas, and analogs thereof, that exert an ACC activity-inhibiting effect that is effective in the treatment of obesity, hyperlipemia, fatty liver, hyperglycemia, impaired glucose tolerance, diabetes, diabetic complications (diabetic peripheral neuropathy, diabetic nephropathy, diabetic retinopathy, and diabetic macroangiopathy, hypertension, arteriosclerosis), hypertension, and arteriosclerosis.

An intraocular lens arrangement having positive or negative lens with a frame that extends from the lens to provide diametrically opposed upper and lower frame sections. A first lens linkage has its first end attached to the upper frame section with at least two points of contact with the upper frame section. A second lens linkage has its first end attached to the lower frame section with at least two points of contact with the lower frame section. A second end of said first lens linkage and a second end of the second lens linkage are attached to a sulcus or zonule member to provide relatively large movement of the lens with a small movement of the ciliary muscle during accomodation response of the eye, and wherein the movements during the accommodation response are along the optical axis of the eye and are controlled in order to improve the image on the retina of objects viewed by the eye over a wide range of distances. The lens is preferably a positive lens with the appropriate frame. The haptics that connect the frame to the sulcus member is at least two pairs of haptics or alternatively a pair of single curved haptics that each have a sulcus connecting member. The intraocular lens cand contain a positive lens as note above along with a negative lens.

An intraocular lens for amblyopia designed in consideration of normalizing vision as well as magnifying vision, is provided with an optical part having predetermined refractive power, which includes front and rear side refractive surfaces, a supporting part for supporting the optical part within the eye, a first reflecting part formed at a rear surface side of the optical part for reflecting an incident light bundle, which has passed through the front surface of the optical part, toward the front surface, and a second reflecting part formed at a front surface side of the optical part for reflecting the incident light bundle, which has been reflected by the first one, toward the rear surface, wherein the first and second reflecting parts form a reflecting telescopic system which forms a magnified image on a retina, and at least one of them has a property of transmitting a part of the light bundle.

An object is to provide an artificial vision system ensuring a wide field of view without damaging a retina. In the artificial vision system, a plurality of electrodes (23) are to be implanted so as to stick in an optic papilla of an eye of a patient. A signal for stimulation pulse is generated based on an image captured by an image pick up device (11) to be disposed outside a body of the patient. The electrical stimulation signals outputted from the electrodes (23) based on the signals for stimulation pulse stimulate an optic nerve of the eye, thereby enabling the patient to visually recognize the image from the image pickup device (11).

Methods and a device comprising a controller / processor unit (664), a visual test-pattern unit (660), a competing sensory stimuli generating unit (662), a user input device (666), an ouput device (668) and a storage unit (670) for detecting eye disease and for assessing the clinical stage of an eye disease in an individual is disclosed. The methods include projecting test patterns onto the retina of a tested eye and subjecting the individual to a competing sensory stimuli. The competing stimuli may be of various different sensory modalities including visual, auditory, or other sensory modalities. If the individual perceives a difference in at least one localized part of the perceived image of a test pattern as compared to a predefined reference pattern, the individual provides a response indicative of the difference or differences. The responses are processed to assess the severity of eye disease if a disease is detected, or to determine the clinical stage of a detected eye disease.

A handheld, ocular imaging device and system that employs the camera, processor and programming of a mobile phone, tablet or other smart device coupled to optical elements and illumination elements that can be used to image the structures of the eye in home-based, ambulatory-care, hospital-based, or emergency-care settings, is presented. The modular device provides multi-functionality (fluorescein imaging, fluorescence, brightfield, infrared (IR) imaging, near-infrared (NIR) imaging) and multi-region imaging (retinal, corneal, external, etc.) of the eye along with the added features of image processing, storage and wireless data transmission for remote storage and evaluation. Acquired ocular images can also be transmitted directly from the device to the electronic medical records of a patient without the need for an intermediate computer system.

An Optical Imaging Device of Retinal Function has been developed to detect changes in reflectance of near infrared light from the retina of human subjects in response to visual activation of the retina by a pattern stimulus. The measured changes in reflectance correspond in time to the onset and offset of the visual stimulus in the portion of the retina being stimulated. Any changes in reflectance can be measured by interrogating the retina with a light source. The light source may be presented to the retina via the cornea and pupil or through other tissues in and around the eye. Different wavelengths of interrogating light may be used to interrogate various layers of the retina. Additionally, various novel patterns and methods of stimulation have been developed for use with the imaging device and methods.

Pre-treatment using a xanthin carotenoid (preferably 3R,3′R-zeaxanthin) can improve the benefits and efficacy of photodynamic therapy (PDT), which uses a light-activated drug (such as verteporfin) in patients who suffer from unwanted retinal blood vessel growth, including the “wet” (exudative) form of macular degeneration. Before a PDT treatment, patients are given a regimen of orally-ingested zeaxanthin for a period of at least 1 and preferably at least 2 to 3 weeks, at dosages of at least 3 and preferably at least 10 milligrams per day. Since zeaxanthin imparts a yellowish color to the macula, a preferred dosage should increase a patient's macular pigment density before the PDT treatment is performed.

An apparatus for administering light to effect re-timing of the human body clock is disclosed. In one form, the apparatus includes two pairs of light emitting diodes having an emission wavelength in the range 450 nm to 530 nm and a frame adapted to be worn on the face of a wearer. The frame is arranged to support the two pairs of light emitting diodes so that one pair of the light emitting diodes is supported adjacent a surface of each eye of the wearer. The light emitting diodes of each pair project a light output that illuminates a different area of the retina of a respective eye and are spaced apart so as to provide a viewing zone therebetween.